top of page
The Professional Network for Healthcare Experts
European Commission approves Trodelvy plus Keytruda for first-line PD-L1-positive metastatic triple-negative breast cancer
The approval establishes Trodelvy-based treatment across PD-L1 status in first-line metastatic TNBC in Europe, following the earlier authorisation of Trodelvy monotherapy for patients not eligible for PD-1/PD-L1 inhibitors.
nuaxia
7 hours ago2 min read
CHMP backs Trodelvy plus Keytruda for first-line PD-L1-positive metastatic breast cancer
If authorised, the combination would add an antibody-drug conjugate-based first-line option for eligible European patients with unresectable locally advanced or metastatic triple-negative breast cancer.
nuaxia
Jul 272 min read
bottom of page